Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan.
PLoS One. 2019 Mar 14;14(3):e0208665. doi: 10.1371/journal.pone.0208665. eCollection 2019.
Hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC). Previous studies have identified recurrent nonsense mutations in the HBV large S (LHBs) gene from the liver from HBV core antigen-positive HCC patients. These nonsense mutants have been shown to be oncogenic in mouse xenograft models using a mouse embryonic fibroblast cell line. Here, we expressed in a liver cell line Huh-7 a carboxy terminally truncated protein from a nonsense mutant of the LHBs gene, sW182* (stop codon at tryptophane-182). Although the sW182* protein appeared not to be very stable in the cultured liver cells, we confirmed that the protein can be highly expressed and retained for a prolonged period of time in the hepatocytes in the mouse liver, indicating its stable nature in the physiological condition. In the Huh-7 cells, the sW182* mutant downregulated tumor suppressors p53 and Smad4. This downregulation was reversed by a proteasome inhibitor MG132, implying the involvement of proteasome-based protein degradation in the observed regulation of the tumor suppressors. On the other hand, we found that c-Jun activation domain-binding protein 1 (Jab1) physically interacts with the sW182*, but not wild-type LHBs. RNA interference (RNAi) of Jab1 restored the levels of the downregulated p53 and Smad4. The sW182* mutant inhibited the promoter activity of downstream target genes of the tumor suppressors. Consistently, Jab1 RNAi reversed the inhibition. These results suggest that the LHBs nonsense mutant antagonizes the tumor suppressor pathways through Jab1 in the liver contributing to HCC development.
乙型肝炎病毒(HBV)是肝细胞癌(HCC)的主要原因。以前的研究已经从 HBV 核心抗原阳性 HCC 患者的肝脏中鉴定出 HBV 大 S(LHBs)基因的反复无义突变。这些无义突变体已被证明在使用小鼠胚胎成纤维细胞系的小鼠异种移植模型中具有致癌性。在这里,我们在肝细胞系 Huh-7 中表达了来自 LHBs 基因无义突变体 sW182*(色氨酸 182 处的终止密码子)的羧基末端截断蛋白。尽管 sW182蛋白在培养的肝细胞中似乎不太稳定,但我们证实该蛋白可以在小鼠肝脏中的肝细胞中高度表达并长时间保留,表明其在生理条件下的稳定性。在 Huh-7 细胞中,sW182突变体下调肿瘤抑制因子 p53 和 Smad4。这种下调可以通过蛋白酶体抑制剂 MG132 逆转,暗示在观察到的肿瘤抑制因子调节中涉及蛋白酶体依赖性蛋白降解。另一方面,我们发现 c-Jun 激活域结合蛋白 1(Jab1)与 sW182物理相互作用,但与野生型 LHBs 不相互作用。Jab1 的 RNA 干扰(RNAi)恢复了下调的 p53 和 Smad4 的水平。sW182突变体抑制了肿瘤抑制因子下游靶基因的启动子活性。一致地,Jab1 RNAi 逆转了抑制。这些结果表明,LHBs 无义突变体通过 Jab1 在肝脏中拮抗肿瘤抑制途径,导致 HCC 的发展。